A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma

Cook, N, Basu, B, Smith, D-M et al. (16 more authors) (2018) A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. British Journal of Cancer, 118 (6). pp. 793-801. ISSN 0007-0920

Abstract

Metadata

Authors/Creators:
  • Cook, N
  • Basu, B
  • Smith, D-M
  • Gopinathan, A
  • Evans, J
  • Steward, WP
  • Palmer, D
  • Propper, D
  • Venugopal, B
  • Hategan, M
  • Anthoney, DA
  • Hampson, LV
  • Nebozhyn, M
  • Tuveson, D
  • Farmer-Hall, H
  • Turner, H
  • McLeod, R
  • Halford, S
  • Jodrell, D
Copyright, Publisher and Additional Information: (c) 2018 The Author(s) This work is licensed under the Creative Commons Attribution-Non-Commercial-Share Alike 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
Keywords: pancreatic cancer; g-secretase; notch pathway; gemcitabine
Dates:
  • Accepted: 20 December 2017
  • Published (online): 13 February 2018
  • Published: 20 March 2018
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cancer and Pathology (LICAP) > Clinical Cancer Research (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 10 Dec 2018 11:23
Last Modified: 10 Dec 2018 11:23
Status: Published
Publisher: Springer Nature
Identification Number: https://doi.org/10.1038/bjc.2017.495
Related URLs:

Export

Statistics